BioStock: Ultimovacs reaches proof of concept with UV1 cancer vaccine

Ultimovacs has reported positive phase II overall survival data with its cancer vaccine candidate UV1 in mesothelioma. The data will be presented by the Principal Investigator of the NIPU trial, Professor Åslaug Helland, at the ESMO Congress 2023. BioStock spoke with the the Norwegian biotech’s Director Medical Affairs Espen Basmo Ellingsen to better understand the significance of these results.

Read the interview with Espen Basmo Ellingsen at biostock.se:

Ultimovacs reaches proof of concept with UV1 cancer vaccine - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/